https://www.fiercebiotech.com/biotech/astellas-to-halt-work-at-r-d-subsidiary-amid-restructuring
Astellas Pharma has begun restructuring its operations, with plans to discontinue all work at Astellas Research Technologies, its R&D subsidiary of about 200...
r dastellashaltworksubsidiary
https://www.prnewswire.com/news-releases/kalivir-immunotherapeutics-and-astellas-enter-worldwide-exclusive-licensing-agreement-for-development-and-commercialization-of-vet2-l2-novel-oncolytic-virus-301186994.html
/PRNewswire/ -- KaliVir Immunotherapeutics LLC (CEO: Helena Chaye, Ph.D., J.D., "KaliVir") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji...
licensing agreementimmunotherapeuticsastellasenterworldwide
https://newsroom.astellas.com/our-stories?o=10
Read stories about patient-centered and science-driven healthcare, as told by the experts who bring it to life.
storiesastellas
https://astellas-nephrology.com/?password-protected=login&redirect_to=https%3A%2F%2Fastellas-nephrology.com%2F
astellasnephrology
https://www.clinicaltrials.astellas.com/commitment-to-diversity
At Astellas, we know that diversity in clinical trials is essential for advancing healthcare and making sure everyone benefits from medical innovations.
clinical trialsastellascommitmentdiversity
https://www.macrotrends.net/stocks/charts/ALPMY/astellas-pharma/revenue
Astellas Pharma revenue from 2012 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of...
astellas pharmarevenue
https://www.fiercebiotech.com/biotech/astellas-audentes-reports-third-death-gene-therapy-trial
Audentes Therapeutics has reported a third death in a clinical t
gene therapyastellasaudentesreportsdeath